Navera Investment Management Ltd. Grows Holdings in Thermo Fisher Scientific Inc. $TMO

Navera Investment Management Ltd. boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.6% in the 2nd quarter, Holdings Channel reports. The firm owned 664,893 shares of the medical research company’s stock after purchasing an additional 3,675 shares during the period. Thermo Fisher Scientific accounts for about 4.9% of Navera Investment Management Ltd.’s investment portfolio, making the stock its 12th biggest holding. Navera Investment Management Ltd.’s holdings in Thermo Fisher Scientific were worth $269,516,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of TMO. Mondrian Investment Partners LTD raised its position in Thermo Fisher Scientific by 146.1% during the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company’s stock worth $106,738,000 after buying an additional 127,357 shares during the last quarter. Caledonia Investments PLC raised its position in Thermo Fisher Scientific by 11.5% during the 2nd quarter. Caledonia Investments PLC now owns 111,767 shares of the medical research company’s stock worth $45,299,000 after buying an additional 11,500 shares during the last quarter. Foresight Group Ltd Liability Partnership raised its position in Thermo Fisher Scientific by 3,242.7% during the 1st quarter. Foresight Group Ltd Liability Partnership now owns 58,497 shares of the medical research company’s stock worth $29,113,000 after buying an additional 56,747 shares during the last quarter. Advisors Capital Management LLC raised its position in Thermo Fisher Scientific by 6.7% during the 1st quarter. Advisors Capital Management LLC now owns 127,011 shares of the medical research company’s stock worth $63,201,000 after buying an additional 7,967 shares during the last quarter. Finally, New England Research & Management Inc. raised its position in Thermo Fisher Scientific by 28.6% during the 2nd quarter. New England Research & Management Inc. now owns 2,548 shares of the medical research company’s stock worth $1,033,000 after buying an additional 567 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on TMO. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Thermo Fisher Scientific in a research note on Saturday, September 27th. Evercore ISI upped their price target on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a research note on Tuesday. Robert W. Baird upped their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a research note on Thursday, July 24th. Finally, Wells Fargo & Company lowered their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating on the stock in a research note on Thursday, July 24th. Fifteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $590.60.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $539.54 on Wednesday. The stock has a market cap of $203.73 billion, a price-to-earnings ratio of 31.21, a PEG ratio of 2.95 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97. The company’s 50-day moving average price is $484.90 and its 200 day moving average price is $447.60. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analysts’ expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm’s revenue was up 2.9% on a year-over-year basis. During the same period in the prior year, the company earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.95%.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 400 shares of the stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at approximately $56,937,881. This represents a 0.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,066 shares of company stock valued at $14,182,963. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.